Detection of SARS-CoV-2 in Fecal Samples from Patients with Asymptomatic and Mild COVID-19 in Korea

Hepatology

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

J Hepatol.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J

doi: 10.1016/j.jhep.2020.05.002.

Further Publications

Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission: A COVID-19 Virological and Clinical Review

Gastroenterology.

Ding S, Liang TJ

doi: 10.1053/j.gastro.2020.04.052.

Further Publications

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Gastroenterology.

Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung A, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS, Ng SC

doi: 10.1053/j.gastro.2020.05.048.

Inflammatory Bowel Disease

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Gut

Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T, Contributors to the CLARITY IBD study.

doi: 10.1136/gutjnl-2021-324789

Inflammatory Bowel Disease

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

No abstract available

Gastrointestinal Diseases

Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review

Colorectal Dis.

Gupta S, Parker J, Smits S, Underwood J, Dolwani S

doi: 10.1111/codi.15138.

Hepatology

High rates of 30-day mortality in patients with cirrhosis and COVID-19

J Hepatol.

Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P

doi: 10.1016/j.jhep.2020.06.001.

Further Publications

AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Gastroenterology.

Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB, AGA.

doi: 10.1053/j.gastro.2020.05.001.

Inflammatory Bowel Disease

T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease

J Crohns Colitis

Reuken PA, Andreas N, Grunert PC, Glöckner S, Kamradt T, Stallmach A

doi: 10.1093/ecco-jcc/jjab147

Related content

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission: A COVID-19 Virological and Clinical Review

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review

High rates of 30-day mortality in patients with cirrhosis and COVID-19

AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease